Clinical trial

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

NCT06380660

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-03-22

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2024-03-22Date precision: day

Registry last updated2026-08-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumor, Adultunresolved

BRCA1 Mutationunresolved

BRCA2 Mutationunresolved

Ovarian Cancerunresolved

Breast Cancerunresolved

Prostate Cancerunresolved

Interventions

ACE-86225106 tabletDRUG

Sponsors & collaborators

Acerand Therapeutics (Shanghai) Limitedlead sponsor

Mapped research locations

WuhanHubei, China2 JinanShandong, China2 ShanghaiShanghai Municipality, China1 GuangzhouGuangdong, China1 HangzhouZhejiang, China1 ChangshaHunan, China1 ZhengzhouHenan, China1 ChongqingChongqing Municipality, China1 FuzhouFujian, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06380660 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.